Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05102617 · ClinicalTrials.gov registry record · NA

Post Market Usability Evaluation Of The PicoSure Pro Device

A NA study of Wrinkle and Acne Scars, sponsored by Cynosure.

Completed
Registry status
NA
Development phase
23
Enrollment target
2
Study locations

NCT05102617: Completed NA study of Wrinkle and Acne Scars, sponsored by Cynosure.

NCT05102617 is a NA study of Wrinkle and Acne Scars that has completed, run by Cynosure. The registered enrollment target is 23 participants, below the 119-participant average among 25 other Wrinkle trials with a reported enrollment target (81% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05102617, a NA study of Wrinkle and Acne Scars, has completed, sponsored by Cynosure.

COMPLETED
Registry status
NA
Development phase
23 participants
Enrollment target
2
Study locations

Study Summary

The intended use of the PicoSure and PicoSure Pro devices used in this study is to treat additional patients with the new PicoSure Pro device and collect additional data on the devices.

Primary Outcome

The investigator will grade the improvement they noticed between the baseline image and the follow up image based on the Global Aesthetic Improvement Scale (GAIS), which ranges from 1-5 as follows: Very Much Improved (1), Much Improved (2), Improved (3), No Change (4), Worse (5).

Interventions

  • DEVICE PicoSure Pro Device
  • DEVICE PicoSure Device
  • DRUG Topical Cosmeceuticals

Study Locations (2)

California

  • Center for Dermatology and Laser Surgery - Sacramento

Massachusetts

  • Cynosure, Inc. - Westford

Trial Details

FieldValue
Enrollment Target 23 participants
Start Date 2021-10-21
Est. Completion 2023-03-15
Phase NA
Cynosure

49 total trials

What the finished NCT05102617 record still lists

NCT05102617 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 119-participant average among 25 other Wrinkle trials with a reported enrollment target (81% lower).

The record links to 5 conditions, with Wrinkle appearing as the primary indexed condition, and to 3 interventions - of which PicoSure Pro Device is the first listed.

NCT05102617 reports a single indexed study location in California, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05102617 about?

NCT05102617 is a clinical study titled "Post Market Usability Evaluation Of The PicoSure Pro Device". The intended use of the PicoSure and PicoSure Pro devices used in this study is to treat additional patients with the new PicoSure Pro device and collect additional data on the devices.

What is the current status of trial NCT05102617?

This trial is currently completed. It is a NA study. The enrollment target is 23 participants. The study started on 2021-10-21. Estimated completion is 2023-03-15.

What conditions does trial NCT05102617 study?

This clinical trial studies the following conditions: Wrinkle, Acne Scars, Tattoo Removal, Benign Epidermal Pigmented Lesions, Benign Dermal Pigmented Lesions.

What interventions are being tested in trial NCT05102617?

The interventions under investigation include: PicoSure Pro Device (DEVICE), PicoSure Device (DEVICE), Topical Cosmeceuticals (DRUG).

Who is sponsoring clinical trial NCT05102617?

This trial is sponsored by Cynosure, which has 49 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05102617 being conducted?

This trial has 2 study locations across California, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Wrinkle

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05102617's enrollment target sits among peer trials

23 21st of 25 higher than 5 of 25 other Wrinkle trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Wrinkle trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03616041 · 23 participants

    Capsule Endoscopy for Severe Hematochezia

  • NCT04348747 · 23 participants · Phase 2

    Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

  • NCT04587687 · 23 participants · Phase 2

    Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

  • NCT04715022 · 23 participants · Phase 1

    Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05102617, the US trial registry maintained by the National Library of Medicine. NCT05102617 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.